Cosmo Pharmaceuticals S.p.A. announced that at the Extraordinary Shareholders’ Meeting called on December 22, 2014, 8’968’250 votes of the total 14’225’600 voting shares were present and shareholders approved the proposed capital reduction and board compensation as follows...
SYGNIS AG today announced that it has signed an initial distribution agreement for its first proprietary product with German BioCat GmbH.
Apogenix, a clinical stage biopharmaceutical company, announced today that the final data of the completed phase II clinical trial with APG101 in recurrent glioblastoma has been published in the peer-reviewed journal Clinical Cancer Research.
Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that Ferring’s CORTIMENT® MMX® (budesonide) treatment for the induction of remission in patients with active, mild to moderate Ulcerative Colitis has received marketing approval from 27 European Union member states following the EU Mutual Recognition Procedure (MRP).
Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that Cosmo Holding & Management Group, dievini Hopp biotech GmbH & Co KG and the Heinrich Herz AG/Logistable Group, which together control 65.8% of the issued shares, have indicated their approval of the change of seat and that they will not make use of the right to put shares back to the Company.
WILEX AG (ISIN DE000A11QVV0 / WL6 / FWB) today published its financial report on the first nine months of 2014 (1 December 2013 – 31 August 2014).
Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that the board of directors has resolved to call an extraordinary shareholders meeting in order to propose a change of registered office and seat of management of the Company.
WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that WILEX subsidiary Heidelberg Pharma and Roche extended the existing 2013 licence agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies.
Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that the US Patent Office had issued the notice of allowance of its patent application 13/226,758 for Uceris®.
CyclASol® (cyclosporine A solution formulation in the semi-fluorinated alkane vehicle F4H5) eye drops are safe and well tolerated
CyclASol® is th